Axon posted a disasterous loss of U.S$10m last calendar year.
Its shareholder update of December 2002 said they would inititate R&D constraints and shed some staff to save U.S$4M in this calender year.
Well, by simple arithmetic, Axon was still staring at a U.S$6m deficit.
The only way that they could be running at breakeven, as disclosed in their response to the stock exchange today, is if they have posted a pretty impressive growth in sales.
Break even is boring, but growth, especially at this low market cap, is attractive.
- Forums
- ASX - By Stock
- growth stock
growth stock
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)